Foghorn Therapeutics Inc.
FHTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $8,153 | $7,557 | $5,952 | $2,856 |
| % Growth | 7.9% | 27% | 108.4% | – |
| Cost of Goods Sold | $20,002 | $900 | $0 | $0 |
| Gross Profit | -$11,849 | $6,657 | $5,952 | $2,856 |
| % Margin | -145.3% | 88.1% | 100% | 100% |
| R&D Expenses | $20,002 | $20,892 | $21,626 | $20,508 |
| G&A Expenses | $6,652 | $6,862 | $7,239 | $6,353 |
| SG&A Expenses | $6,652 | $6,862 | $7,239 | $6,353 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$20,002 | $0 | $0 | $0 |
| Operating Expenses | $6,652 | $27,754 | $28,865 | $26,861 |
| Operating Income | -$18,501 | -$21,097 | -$22,913 | -$24,005 |
| % Margin | -226.9% | -279.2% | -385% | -840.5% |
| Other Income/Exp. Net | $2,652 | $3,161 | $4,079 | $4,502 |
| Pre-Tax Income | -$15,849 | -$17,936 | -$18,834 | -$19,503 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$15,849 | -$17,936 | -$18,834 | -$19,503 |
| % Margin | -194.4% | -237.3% | -316.4% | -682.9% |
| EPS | -0.25 | -0.28 | -0.3 | -0.31 |
| % Growth | 10.7% | 6.7% | 3.2% | – |
| EPS Diluted | -0.25 | -0.28 | -0.3 | -0.31 |
| Weighted Avg Shares Out | 63,029 | 62,978 | 62,849 | 62,603 |
| Weighted Avg Shares Out Dil | 63,029 | 62,978 | 62,849 | 62,603 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,032 | $2,309 | $2,692 | $3,096 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $852 | $900 | $827 | $761 |
| EBITDA | -$14,997 | -$17,036 | -$22,086 | -$23,244 |
| % Margin | -183.9% | -225.4% | -371.1% | -813.9% |